Valneva's COVID-19 Vaccine Candidate Using Dynavax's Adjuvant Shows Positive Interim ResultsBenzinga • 04/06/21
French vaccine maker Valneva to launch Phase 3 trial of COVID vaccine it's making with Dynavax after positive resultsMarket Watch • 04/06/21
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ AdjuvantPRNewsWire • 04/06/21
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001GlobeNewsWire • 04/06/21
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine CandidatePRNewsWire • 03/24/21
Dynavax Stock Is Trading Higher As Adjuvanted COVID-19 Vaccine Trial Moves ForwardBenzinga • 03/24/21
Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences ConferencePRNewsWire • 03/01/21
Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Has Dynavax Technologies (DVAX) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/24/21
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted VaccinePRNewsWire • 02/19/21
Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/18/21
Dynavax Technologies (DVAX) Gains As Market Dips: What You Should KnowZacks Investment Research • 02/17/21
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1Seeking Alpha • 02/07/21